Jeff Chen

Open Book Extracts, announced the launch of its third trial on rare cannabinoids, in partnership with Radicle Science. Radicle Science is conducting the four-week blinded, randomized, placebo-controlled, institutional review board approved trial comparing the effects of various OBX cannabinoid...

Radicle Science will launch large-scale, blinded, placebo-controlled clinical trials on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, pain, stress, and anxiety. These unprecedented Radicle Discovery studies will involve...

Charlotte's Web Holdings, (TSX:CWEB) (OTCQX: CWBHF) reported positive results from a randomized, controlled, clinical trial study which evaluated the effectiveness of its hemp-derived CBD extracts. Charlotte's Web participated in the Radicle ACES (Advancing CBD Education and...

Reviewing Amgen, Inc. (NASDAQ: AMGN)'s third-quarter results, Cowen said the results were boring but very safe. The firm maintains its Buy rating and $209 price target for the shares of the company. At the time of writing, shares of Amgen were trading down 1.67 percent at $174.54. Analysts...